.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Pimecrolimus Impresses

July 1, 2001

VIENNA - The ascomycin derivative pimecrolimus (ASM 981, Elidel) - currently in Phase III trials for the treatment of atopic dermatitis (topical) and psoriasis (oral) - exhibits skin-specific anti-inflammatory activity and has low potential for immunosuppression in both its topical and oral formulations.